Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bortezomib plus R-DHAP versus R-DHAP before BEAM and autologous stem cell transplantation in relapsed or refractory diffuse large B-cell lymphoma
2012-000924-16Phase 2Completed
- Sponsor
- Fondazione Italiana Linfomi
- Start
- Oct 2012
- Modality
- Reversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of bortezomib in diffuse large B-cell lymphoma (DLBCL) (2 arms), sponsored by Fondazione Italiana Linfomi. Primary endpoint: Complete response rate. Started Oct 2012; status: completed.
02
Drugs
bortezomib
03
Conditions
diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on 2012-000924-16.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2012-000924-16.